https://doi.org/10.4081/cdr.13.13300
Refractory sarcoidosis presenting as chylothorax: a case report
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 January 2025
Sarcoidosis is a systemic granulomatous autoinflammatory disease that primarily affects lymphoid organs, the skin, and the lungs. While recurrent pleural effusion is documented in sarcoidosis, chylothorax is exceedingly rare.
We present a male patient in his seventies who presented to the emergency department with long-standing fatigue, a ten-kilogram weight loss over six months, new-onset snoring, and nasal congestion. Evaluations, including respiratory function tests and chest computed tomography, revealed findings consistent with sarcoidosis, such as hilar lymphadenopathy, reduced carbon monoxide diffusion, and elevated serum angiotensin-converting enzyme levels, along with pleural effusion. Analysis of the pleural fluid showed it to be exudative, with high triglycerides level. We concluded that chylothorax resulted from extensive lymph node involvement.
During two years of follow-up, combinations of methylprednisolone and other immunosuppressants were ineffective, leading to disease progression. Infliximab was then initiated, resulting in a dramatic clinical response and improvement in Positron Emission Tomography/Computerized Tomography (PET/CT) imaging.
Downloads
Perlman DM, Sudheendra MT, Furuya Y, et al. Clinical presentation and treatment of high-risk sarcoidosis. Ann Am Thorac Soc 2021;18:1935-47. DOI: https://doi.org/10.1513/AnnalsATS.202102-212CME
Chopra A, Foulke L, Judson MA. Sarcoidosis associated pleural effusion: clinical aspects. Respir Med 2022;191:106723. DOI: https://doi.org/10.1016/j.rmed.2021.106723
Israeli-Shani L, King D, Epstein Shochet G, et al. Chylothorax associated with sarcoidosis: a review of the literature. Sarcoidosis Vasc Diffuse Lung Dis 2022;39:e2022039.
El Jammal T, Jamilloux Y, Gerfaud-Valentin M, et al. Refractory sarcoidosis: a review. Ther Clin Risk Manag 2020;16:323-45. DOI: https://doi.org/10.2147/TCRM.S192922
Rezaee M, Zangiabadian M, Soheili A, et al. Role of anti-tumor necrosis factor-alpha agents in treatment of sarcoidosis: a meta-analysis. Eur J Intern Med 2023;109:42-9. DOI: https://doi.org/10.1016/j.ejim.2022.12.003
Riley LE, Ataya A. Clinical approach and review of causes of a chylothorax. Respir Med 2019;157:7-13. DOI: https://doi.org/10.1016/j.rmed.2019.08.014
Bhattarai B, Schmidt F, Devkota A, et al. A case of chylothorax in a patient with sarcoidosis: a rare and potentially fatal complication. J Community Hosp Intern Med Perspect 2015;5:28300. DOI: https://doi.org/10.3402/jchimp.v5.28300
Sunnetcioglu A, Sertogullarindan B, Batur A, Bayram I. A case of sarcoidosis with pleural involvement. Clin Respir J 2018;12:334-6. DOI: https://doi.org/10.1111/crj.12504
Yamashita H, Kubota K, Mimori A. Clinical value of whole-body PET/CT in patients with active rheumatic diseases. Arthritis Res Ther 2014;16:423. DOI: https://doi.org/10.1186/s13075-014-0423-2
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
